On November 28, 2017, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers announcing further details on the continuous evaluation process.

Effective today, INESSS is initiating the consultation period for drug products for which a listing request was filed between October 2, 2017 and November 27, 2017 and deemed admissible for a scientific evaluation. In addition, following the introduction of the mandatory notice, INESSS is also initiating consultation for other drug products based on their anticipated date of submission for filing a listing request. The consultation period for each drug product is seven weeks.

Citizens, health professionals, patients and their caregivers, as well as their associations or groups may provide comments on any of the drug products by the specified deadline. To do so, INESSS invites you to fill out one of the two questionnaires on their website or to send your comments by e-mail to:

plan.commentaires.inscription@inesss.qc.ca

Consult the work plan to find out all the drug products with pending submissions for evaluation, awaiting evaluation or being evaluated by INESSS as well as deadlines for submitting your comments. Please note that the work plan is updated at the beginning of each week.

For more information, please consult the INESSS website.